Source comparison
Step 2: Determine Weekly vs Twice-Weekly Dosing Based on Research Goals
CJC-1295 with DAC has a plasma half-life of 6–8 days, meaning a single injection sustains elevated GH levels throughout the week. This is mechanistically different from unmodified GHRH analogues like Sermorelin or CJC-1295 without DAC, which require daily or m
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC has a plasma half-life of 6–8 days, meaning a single injection sustains elevated GH levels throughout the week. This is mechanistically different from unmodified GHRH analogues like Sermorelin or CJC-1295 without DAC, which require daily or multiple-daily injections due to half-lives under 30 minutes. The DAC modification. A maleimide-linked albumin-binding moiety. Prevents renal clearance and enzymatic degradation, extending bioavailability from minutes to days.
- Standard research dosing ranges from 1mg once weekly to 1mg twice weekly (Monday and Thursday, or similar 3–4 day spacing). Once-weekly protocols maintain GH elevation with minimal injection frequency, suitable for baseline anabolic signal studies. Twice-weekly protocols amplify peak GH levels and may produce more pronounced downstream effects on IGF-1 expression, though the marginal benefit diminishes due to CJC-1295's sustained duration. A 2015 pharmacokinetic analysis found that 2mg weekly (administered as 1mg × 2) increased mean IGF-1 AUC by 18% compared to 1mg weekly. A measurable but modest difference.
- Dosing above 2mg weekly does not proportionally increase GH output. GHRH receptor saturation occurs at physiological concentrations, meaning excess peptide binds without additional signalling effect. Researchers pursuing maximum anabolic signal often combine CJC-1295 with a GHRP (growth hormone-releasing peptide) like Ipamorelin or GHRP-2, which act through ghrelin receptors to synergistically amplify GH pulses. That combination produces GH release 3–5× baseline. Far beyond what either peptide achieves alone. For standalone CJC-1295 use, 1–2mg weekly represents the evidence-supported dosing window. CJC1295 Ipamorelin 5MG 5MG pre-blends both peptides at research-optimised ratios for synergistic GH release protocols.